Illumina (ILMN) is a Top-Ranked Growth Stock: Should You Buy?

Company Overview - Illumina Inc. is based in San Diego, CA, and provides sequencing and array-based solutions for genetic and genomic analysis across various markets, including research and clinical settings. Its customer base includes genomic research centers, academic institutions, government laboratories, hospitals, and companies in pharmaceuticals, biotechnology, commercial molecular diagnostics, and consumer genomics [11]. Investment Ratings - Illumina has a Zacks Rank of 3 (Hold) and a VGM Score of A, indicating a solid position in the market [12]. - The company is considered a potential top pick for growth investors, with a Growth Style Score of A, forecasting a year-over-year earnings growth of 6.2% for the current fiscal year [12]. Earnings Estimates - In the last 60 days, five analysts have revised their earnings estimates higher for fiscal 2026, with the Zacks Consensus Estimate increasing by $0.10 to $5.14 per share [12]. - Illumina has an average earnings surprise of +10.1%, suggesting a positive trend in earnings performance [12]. Conclusion - With a strong Zacks Rank and top-tier Growth and VGM Style Scores, Illumina is recommended for investors' consideration [13].